- Home
- ANVS vs KPTI Comparison
ANVS vs KPTI Comparison
Compare ANVS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | KPTI |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 94.6M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ANVS | KPTI |
|---|---|---|
| Price | $3.61 | $7.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.50 | ★ $22.17 |
| AVG Volume (30 Days) | ★ 847.8K | 219.2K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,530,000.00 |
| Revenue This Year | N/A | $3.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $3.51 |
| 52 Week High | $5.60 | $12.45 |
Technical Indicators
Market Signals| Indicator | ANVS | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 65.63 |
| Support Level | $3.46 | $5.99 |
| Resistance Level | $4.04 | $7.70 |
| Average True Range (ATR) | 0.35 | 0.54 |
| MACD | -0.13 | 0.12 |
| Stochastic Oscillator | 12.29 | 86.03 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.